Sagent Pharmaceuticals
Sagent Pharmaceuticals®, a subsidiary of the Nichi-Iko Group, is a manufacturer of pharmaceutical injectables and biosimilars. Sagent’s internal and external manufacturing offer flexibility in their product portfolio across diverse therapeutic categories and in packaging including vials, syringes and premix bags. Sagent offers more than 60 injectable products across the anti-infective, oncology and critical care categories. All of Sagent’s products feature PreventIV Measures packaging and labeling, Sagent’s approach to packaging and labeling that may help reduce the risk of medication errors. Company history. In 2007, Sagent was formed and launched its first injectable  product. In 2011, the company filed for IPO offering 5,750,000 shares of common stock at a price of $16 per share. In 2014, the company purchased Omega Laboratories Limited and launched its first specialty pharmaceutical product. In 2015, the company sold Sagent (China) Pharmaceuticals to Nanjing King-Friend Biochemical Pharmaceutical Co. In 2016, the company was acquired by Nichi-Iko Pharmaceuticals. In 2019, the company acquired a sterile injectable plant in Raleigh, NC. Omega Laboratories Limited received FDA approval to manufacture sterile injectable products for the US market.